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Epigeneticsa b s t r a c t
DNAmethylation analysis has become an integral part of biomedical research. For high-throughput appli-
cations such as epigenome-wide association studies, the Inﬁnium HumanMethylation450 (450K) Bead-
Chip is currently the platform of choice. However, BeadChip processing relies on traditional bisulﬁte
(BS) based protocols which cannot discriminate between 5-methylcytosine (5mC) and 5-hydroxymethyl-
cytosine (5hmC). Here, we report the adaptation of the recently developed oxidative bisulﬁte (oxBS)
chemistry to speciﬁcally detect both 5mC and 5hmC in a single workﬂow using 450K BeadChips, termed
oxBS-450K. Supported by validation using mass spectrometry and pyrosequencing, we demonstrate
reproducible (R2 > 0.99) detection of 5hmC in human brain tissue using the optimised oxBS-450K
protocol described here.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
DNA methylation studies have been traditionally concerned
with 5-methylcytosine (5mC), mostly in the context of CpG dinu-
cleotides, which until recently was the only epigenetic modiﬁca-
tion of DNA with known biological function. The rediscovery of
5-hydroxymethylcytosine (5hmC) in mammalian DNA has opened
up an exciting new area of epigenetic research concerning the
potential role of 5hmC in both normal development and disease
progression [1,2]. 5hmC has been proposed to be an intermediate
in an active DNA demethylation pathway and may also be a stable
epigenetic modiﬁcation in its own right, contributing unique
regulatory functions to the epigenome [3].
Current methods for proﬁling 5hmC at a genome-wide level rely
largely on sequencing-based protocols that are both costly and
time-consuming. In addition, they require a high degree of exper-
tise with the chosen assay for successful implementation. The Inﬁ-
nium HumanMethylation450 BeadChip is a widely-used, robust
and reliable tool for DNA methylation proﬁling [4,5], suitable for
high-throughput sample processing and is therefore the platform
of choice for current epigenome-wide association studies [6,7].The 450K array interrogates over 480,000 CpG sites in the human
genome, making it an appropriate tool for 5hmC detection as this
modiﬁcation has been reported to occur exclusively in the CpG
context in both mammalian embryonic stem cells and frontal cor-
tex tissue [8–10]. However, current workﬂows for this microarray
rely on sodium bisulﬁte conversion of DNA, which discriminates
between methylated and unmethylated cytosine bases within the
genome but cannot differentiate between 5mC and 5hmC [11].
The recent development of oxidative bisulﬁte (oxBS) chemistry
presents an opportunity to adapt bisulﬁte-based 5mC proﬁling
technology for 5hmC detection [9]. Here we describe low- and
high-input protocols for genome-wide proﬁling of 5hmC by cou-
pling oxBS chemistry and the Inﬁnium 450K BeadChip (oxBS-
450K). Alternative approaches also using oxBS or Tet-assisted
bisulﬁte (TAB) chemistries have been developed by Field et al.
[12] and Chopra et al. [13], respectively. In brief, oxBS involves a
selective oxidation step prior to bisulﬁte conversion of genomic
DNA that converts 5hmC residues to 5-formylcytosine (5fC) with
high efﬁciency. 5fC behaves in a manner analogous to unmodiﬁed
cytosine under bisulﬁte conditions, allowing only true 5mC posi-
tions to be detected as cytosine after oxidative bisulﬁte conversion
and PCR ampliﬁcation of the DNA sample. Subtraction of oxBS-
generated methylation proﬁles from standard BS-only methylation
proﬁles allows for the detection of hydroxymethylated cytosine
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sion leads to potential overestimation of 5mC levels in a given
sample due to the presence of 5hmC, the oxBS-450K method gen-
erates a more accurate 5mC proﬁle by removing the confounding
factor of 5hmC.
Global 5hmC levels are known to vary considerably between
tissue types and have been found to be highest in the brain
[14,15] and so the distribution of 5hmC in this tissue may be of
particular interest. Here, we show that the Inﬁnium 450K can be
used to successfully detect 5hmC in three distinct genomic DNA
samples (two brain and one whole blood) by comparison of
BS- and oxBS-450K datasets and provide validation of our reported
5hmC signal using independent technologies.2. Materials and methods
2.1. DNA samples
All procedures followed are in accordance with the ethical
standards of the Helsinki declaration (1964, 2008) of the World
Medical Association. Human brain genomic DNA from a 33 year-
old male was obtained from AMSBIO (catalogue #D1234035, lot
#B701205; referred to as ‘brain1’). Human frontal cortex DNA
was collected according to Ethical Approval obtained from the
Berkshire Local Research Ethics Committee (REC 08/H0505/165),
with informed written consent (referred to as ‘brain2’). Pooled
(male and female) whole blood DNA was obtained from blood
donations of volunteers from the UCL Cancer Institute.
2.2. Oxidative bisulﬁte (oxBS) and bisulﬁte-only (BS) conversion
workﬂows
We tested two protocols (low and high input) and report the
results for both to highlight critical steps and provide insights into
their dynamics.
2.2.1. Low-input oxBS-450K protocol
1 lg DNA per sample was processed using a trial version of the
TrueMethyl 24 kit (CEGX). Samples were split evenly into two ali-
quots of 500 ng processed through either the BS-only or oxBS
conversion workﬂow. Each aliquot was subjected to an initial
buffer exchange step using a spin column format and eluted in
ultra-pure water. The full eluate (22 ll per sample) was carried
forward. Samples were denatured using the provided denaturing
solution for 30 min at 37 C, in a total reaction volume of 24 ll
and immediately taken forward to oxidation. 1 ll of the provided
oxidant solution was added to each sample undergoing the oxBS
workﬂow only (1 ll of ultra-pure water was added to BS-only sam-
ples for mock oxidation). All samples were incubated for 30 min at
40 C. Oxidised samples were equilibrated to room temperature
before proceeding immediately to bisulﬁte conversion. Bisulﬁte
reagent solution was prepared as described in the TrueMethyl
protocol and 170 ll was added to each 25 ll oxidation reaction
mixture. Finally, 5 ll of bisulﬁte additive was added to each
reaction, bringing the total volume to 200 ll. All reactions were
incubated using bisulﬁte-speciﬁc thermal cycling conditions (see
Supplementary information). Converted DNAs were puriﬁed using
the provided spin columns and 4 ll of each sample eluate was used
as input into the Inﬁnium 450K array.
2.2.2. High-input oxBS-450K protocol
4 lg DNA per sample was processed using the TrueMethyl
protocol for 450K analysis (Version 1.1, CEGX™). The protocol
was performed as described, with 2 minor alterations. First, the ini-
tial shearing step of DNA was performed using a Bioruptor(Diagenode™). The DNA was diluted into a total volume of 50 ll
in 1.5 ml microtubes and sonicated for 30 s on setting ‘H’. 10 ll
was set aside for visualisation on a 2% agarose gel to conﬁrm cor-
rect DNA fragmentation (all610 kb). Secondly, the remaining 40 ll
(3.2 ug) of sheared DNA was split into 2  20 ll aliquots and
puriﬁed using Agencourt AMPure XP beads using a modiﬁed
protocol (http://www.cambridge-epigenetix.com/uploads/ﬁles/
TrueMethyl24_UGuide.pdf, TrueMethyl 24 kit user guide,
CEGX™). Each sample was eluted in 20 ll ultra-pure water and
then processed either through the oxBS or BS-only workﬂow as
outlined in the TrueMethyl user guide. 7 ll of the ﬁnal eluate
was used as input into the Inﬁnium 450K array, made possible
by adding 1 ll of 0.4 N NaOH to each sample rather than the
standard 4 ll of 0.1 N NaOH when setting up the MSA4 plate.2.3. 450K BeadChip processing and data analysis
450K BeadChips were processed by UCL Genomics following the
manufacturer’s recommendations and data was analysed using the
Chip Analysis Methylation Pipeline (ChAMP) implemented in R and
available from Bioconductor [16]. Brieﬂy, raw IDAT ﬁles were used
as input data and probes were ﬁltered by their raw intensity values
using a detection p-value threshold of 0.01. Probes corresponding
to the X and Y chromosomes were removed from the dataset as
both male and female samples were being analysed. The data
was then normalised using the SWAN method [17], producing a
ﬁnal dataset containing 432,056 probes and their corresponding
beta values for each sample for further downstream analysis. The
R package pvclust was used for multiscale bootstrap resampling
(1000 replications) for hierarchical cluster analysis.2.4. Oxidative bisulﬁte pyrosequencing (oxBS-pyroseq)
50 bp windows containing at least 2 probes showing a hydrox-
ymethylation level of 30% or higher (based on the AMSBIO brain
dataset) were selected for validation by oxBS-pyroseq. Primers
were designed using PyroMark Assay Design 2.0 software (see
supplementary information for sequences and probe IDs). Two ali-
quots of AMSBIO human brain DNA underwent either oxidative
bisulﬁte or bisulﬁte-only conversion (as detailed in Section 2.2)
and were PCR ampliﬁed using a Pyromark PCR kit (Qiagen, cat.
#978703) under the following thermocycling conditions: 95 C
for 15 min, (94 C for 30 s, 66 C (0.5 C per cycle) for 30 s, 72 C
for 30 s)  13 cycles, (94 C for 30 s, 56 C for 30 s, 72 C for
30 s)  50 cycles, 72 C for 10 min. Assays were run on a PyroMark
Q96 ID system and results were analysed using Pyro Q-CpG 1.0.9
software. Methylation scores at each CpG site were normalised
against a linear calibration curve and 5hmC levels calculated by
subtraction of oxBS from BS-only methylation calls.2.5. Mass spectrometry
500 ng of genomic DNA was incubated with 5 U of DNA Degra-
dase Plus (Zymo Research) at 37 C for 3 h. The resulting mixture of
20-deoxynucleosides was analysed on a Triple Quad 6500 mass
spectrometer (AB Sciex) ﬁtted with an Inﬁnity 1290 LC system
(Agilent) and an Acquity UPLC HSS T3 column (Waters), using a
gradient of water and acetonitrile with 0.1% formic acid. External
calibration was performed using synthetic standards, and for accu-
rate quantiﬁcation, all samples and standards were spiked with
isotopically labelled nucleosides. 5mC and 5hmC levels are
expressed as a percentage of total cytosines.
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Global 5hmC levels are known to be lower than 5mC levels and
more varied between different tissues [14,15]. To test the oxBS-
450K protocol, we therefore selected tissues expected to have high
(two types of brain tissue) and low (whole blood) levels of 5hmC
and conﬁrmed their percentage by quantitative LC–MS to be
0.039% for whole blood and 0.924% and 1.107% for the two brain
samples, respectively. In comparison, the corresponding 5mC
levels were 4% in all three samples.
3.1. Identiﬁcation of 5hmC
5hmC detection was achieved by identifying differentially
methylated CpG sites between the BS- and oxBS-treated replicates
within each sample set. The beta value associated with each probe
on an array reﬂects the methylation level at that particular location
on a scale of 0–1, where 0 is unmethylated and 1 is fully
methylated.
Beta values resulting from BS treatment represent the total
methylation score (5mC and 5hmC) as both cytosine modiﬁcations
undergo bisulﬁte conversion to uracil with comparable efﬁciency.
In contrast, beta values resulting from oxBS treatment represent
only the 5mC level at the corresponding probe locations. Therefore
normalised beta values were used to calculate delta beta (Db) val-
ues for each probe by subtraction of the oxBS beta value from the
BS-only beta value. The Db score is a reﬂection of the 5hmC level at
each particular probe location.
Unsupervised hierarchical clustering of this dataset showed a
clear separation between blood, brain1 and brain2 and also
between treatment options, with both BS-only and oxBS-treated
replicates of each sample clustering in pairs (Fig. 1A). The corre-
sponding density proﬁles show a clear reduction of methylation
signals after oxBS treatment (Fig. 1B).
Using this method, both positive and negative Db scores were
calculated. Positive Db values represent potential sites of 5hmC;
negativeDb values, or ‘hypermethylation’ in the oxBS-treated sam-
ple, were not expected as the oxidation reaction is unidirectional
and thus are likely to reﬂect background noise generated by this
method. Fig. 2A shows the Db distribution across all probes for
the brain1 sample, displaying signiﬁcantly more positive Db scores
than negative, as expected. Less than 3% of all negative Db scores
correspond to a 5hmC level of more than 10%, however over 30%
of all positive Db scores correspond to a 5hmC level over 10%. In
addition, Fig. 2B shows that the largest Db scores are associated
with the most signiﬁcant p-values and that signiﬁcance falls awayFig. 1. QC plots for 450K dataset generated using low-input protocol. (A) Unsupervised h
(brain and blood) and also between BS-only and oxBS conversion. ‘‘Au’’ ﬁgures, in red, refe
p-values (%). (B) Density plot of normalised beta values for all 12 samples. Beta values
methylated peak is seen in the oxBS conversion samples, corresponding to lower globalas the Db values approach zero, as expected. Furthermore, fre-
quency plots of all probes according to their associated p-values
(Fig. 3) show that the majority of Db values above zero represent
signiﬁcant differences in methylation score (p 6 0.05). In contrast,
the p-values associated with negative Db scores are distributed
across the entire range (0–1), with increasing numbers of probes
associated with higher p-values. This is consistent with the idea
that the negative Db scores represent false differences in methyla-
tion score between the paired BS-only and oxBS datasets.
There are various ways to deﬁne an appropriateDb threshold to
identify a probe-set of signiﬁcantly hydroxymethylated cytosines,
including shrinkage estimation of variances, but this approach
requires each sample to be run in multiple (3–4) replicates result-
ing in extra costs [12]. As the amount of available genomic DNA is
often limiting, we based our strategy on running two replicates per
sample and opted for using a conservative threshold of DbP 0.3,
or minimum 30% 5hmC, followed by validation. Using this
approach, we identiﬁed 6578 and 7692 probes in our brain1 and
brain2 samples, respectively, in contrast to just 801 probes in
whole blood DNA. Inclusion of a third technical replicate of the
brain1 sample, however, increased the statistical power of the
dataset by allowing the Db calculations to reach statistical signiﬁ-
cance. We were able to use a BH-adjusted p-value threshold of 0.05
to call 5hmC, which dramatically increased the probe number
because any signiﬁcant Db values in the range of 0–30% 5hmC
could now be identiﬁed alongside the more highly hydroxymethy-
lated probes, resulting in the detection of 64,720 signiﬁcant probes
in total. Of these, only 117 sites were associated with negative (but
nevertheless signiﬁcant) Db scores, corresponding to a false dis-
covery rate of less than 0.002. 5hmC levels fell within the range
of 4–59%, with a mean level of 18% 5hmC across all positive
5hmC probe sites whilst all negative Db scores corresponded to
less than 20%.
While the low-input oxBS-450K protocol only requires 1 lg
starting DNA, the high-input protocol requires 4 lg DNA but results
in much improved sensitivity and reproducibility. Using the same
detection p-value threshold of 0.01 as for the low-input protocol
to ﬁlter probes, we found that the technical replicates showed an
improved correlation of R2 > 0.99 compared to R2 > 0.95 for the
low-input protocol, comparable to current ‘gold-standard’ bisulﬁte
conversion protocols. Comparison of BS-only and oxBS datasets
using just two replicates per sample was sufﬁcient to call 165,495
5hmC sites (BH-adjusted p-value < 0.05) with just 627 false positive
probes associated with a negative Db score (Fig. 4). 5hmC levels
were detected in the range of 4–57%, with a mean 5hmC level of
15%. In contrast, negative Db values all fell below 20%.ierarchical clustering of all 12 samples show clear separation between tissues types
r to approximately unbiased p-values (%); ‘‘bp’’ numbers, in green, refer to bootstrap
show a bimodal distribution for BS-only conversion samples, whilst a left-skewed
methylation levels.
Fig. 2. Delta beta (Db) distribution in brain1 sample. (A) Db distribution across all probes after ﬁltering. (B) Db distribution against their associated p-value. Data points
highlighted in blue indicate those probes called as hydroxymethylated (DbP 0.3 and corresponding p-value <0.05).
Fig. 3. Frequency distribution of all probes according to their associated p-value. (A) Frequency distribution of all probes associated with a Db > 0, or potential sites of 5hmC.
(B) Frequency distribution of all probes associated with a Db < 0, i.e. false positives.
12 S.K. Stewart et al. /Methods 72 (2015) 9–15Analysis of the signiﬁcant but negative Db probes between the
low- and high-input protocols for the brain1 sample suggests that
the locations of these negative sites are random: 117 sites were
called by the low-input (3-replicate) method compared to 627
with the high-input method, yet only 8 negative Db sites were
found in common between the two (the increase in negative probenumber is a reﬂection of an overall increase in the number of sig-
niﬁcant probes identiﬁed using the high-input method). Despite
showing statistically signiﬁcant b value differences, these pseudo
false positives cannot reﬂect true differences in methylation level
at these probe sites and should be ﬁltered out before further
downstream data analysis.
Fig. 4. 5hmC levels across all signiﬁcantly hydroxymethylated probes. (A) Frequency distribution of 5hmC levels, expressed as a Db score, across all 64,720 5hmC sites in the
brain1 sample processed in triplicate with the initial protocol. (B) Frequency distribution of 5hmC levels, expressed as a Db score, across all 165,495 5hmC sites in the brain1
sample, processed in duplicate with the optimised protocol. Both protocols detect similar ranges.
Fig. 5. Correlation matrix for low- and high-input oxBS-450K protocols. The high-input protocol results in correlations of R2 > 0.99 for both oxBS and BS-only replicates,
comparable to that of an alternative commercially-available bisulﬁte conversion kit (referred to as the reference protocol). The amount of input DNA needed per conversion
workﬂow is indicated in the table. Note that processing of at least two replicates per sample through both BS-only and oxBS workﬂows is required to calculate 5hmC levels.
Despite high correlations between replicates for both protocols, the embedded bar chart shows a trend of greatly reduced 5hmC call rate (number of probes identiﬁed with
signiﬁcant 5hmC content) when using lower amounts of input DNA.
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different protocols shows that overlap is high, supporting our con-
clusion that these are sites of genuine 5hmC. 83.6% of the 5hmC-
containing sites initially called by the low-input, 2-replicate
method remained signiﬁcantly hydroxymethylated with the addi-
tion of a third replicate (5498 of 6578). This ﬁgure increases to94.2% when comparison is made to the high-input, 2-replicate
dataset. Moreover, only 3.5% of the 5hmC probes called by the
low-input method fail to reach signiﬁcance when either replicate
number or DNA input is increased, suggesting that the false posi-
tive rate of our low-input, 2-replicate method is fairly low (Supple-
mentary Fig. 1).
Fig. 6. Probe distribution according to genomic features. (A) Distribution of all probes after ﬁltering (432,056 total) on 450K BeadChip. (B) Distribution of hydroxymethylated
probes (6578 total) in brain1 sample. (C) Enrichment of 5hmC probes according to various genomic regions. Signiﬁcant enrichment is seen in the gene body, and to a lesser
extent 1500 bp upstream of the TSS. Conversely, signiﬁcant depletion is seen in the proximal promoter region (TSS200) and 1st exon.
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on just two replicates results in detection of 5hmC at over twice
the number of probes compared to the low-input protocol using
three replicates. However, both the mean and range of 5hmC levels
detected is very similar in both cases, suggesting that using lower
amounts of input DNA does not necessarily affect the quality of the
array data produced, but does severely limit the number of probes
whose Db values reach statistical signiﬁcance. The correlation
matrix shown in Fig. 5 is intended to help guide potential users
on which protocol to use.
3.2. Distribution of 5hmC
We used our probe sets of signiﬁcant 5hmC sites to investigate
the distribution of 5hmC within different genomic features, com-
pared to the overall distribution of probes present on the array.
The following categories were used for classiﬁcation of each probe:
30UTR region, 50UTR region, 1st exon, 200 bp window upstream of
the TSS (TSS200), 1500 bp window upstream of the TSS (TSS1500),
intergenic region or gene body. A permutation test was performed
to calculate percentage enrichment for 5hmC within each feature
(Fig. 6) and 5hmC was found to be signiﬁcantly enriched in the
gene body in all three DNA samples. This is consistent with previ-
ous studies concerning the genomic distribution of 5hmC [13,18].
Conversely, 5hmC was found to be signiﬁcantly depleted from pro-
moter regions (deﬁned as within 1500 bp upstream of TSS) and
from CpG islands (Supplementary Fig. 2), which agrees with sev-
eral published studies that describe an inverse correlation between
5hmC and CpG density at the promoter [9,13,19].
3.3. Validation of 5hmC
We used two methods (LC–MS and oxBS-pyroseq) to validate
5hmC identiﬁed with oxBS-450K. On the global level, we used
quantitative LC–MS to conﬁrm that each of our samples did indeed
contain 5hmC levels suitable for detection with oxBS-450K. Using
the average of two replicates, we established that the 5hmC levels
of both brain samples were similar, at around 1% of total cytosine
bases (0.92% in brain1 and 1.11% in brain2), whilst the whole blood
sample contained only low levels of 5hmC, at 0.04% of total cyto-
sine as expected. In contrast, 5mC levels in all three samples were
broadly consistent at around 4% of total cytosine. The overall
pattern of total 5hmC content per sample correlated well with
the observed 5hmC signal from the 450K array data, where we
observed ten-fold higher numbers of probes with signiﬁcant
5hmC in the brain as compared to whole blood (Supplementary
Fig. 3).On the single cytosine level, we used quantitative oxBS-pyroseq
to validate selected 5hmC sites identiﬁed with oxBS-450K in our
brain1 sample. The hydroxymethylation status of six individual
CpG sites across three genomic regions was conﬁrmed using this
assay (Supplementary Fig. 4), with 5hmC levels differing by less
than 10% between the 450K array and pyrosequencing assay. In
addition, our validation results suggest that there is little differ-
ence in the accuracy of 5hmC calling depending on the 450K pro-
tocol used, as both low-input and high-input methods generated
5hmC levels within 10% of the pyrosequencing readout.4. Conclusions
We have shown that oxidative bisulﬁte chemistry can be com-
bined with the 450K DNA methylation microarray to reliably
detect 5hmC and 5mC in the human genome. The oxBS-450K pro-
tocol presented here results in highly reproducible technical repli-
cates, comparable to current ‘gold-standard’ bisulﬁte conversion
kits. Our analysis shows that 5hmC can be detected at statistically
signiﬁcant levels at over 30% of all CpG sites interrogated on the
array, with a mean 5hmC level of 15% in a human brain sample.
Whilst the use of an optimised protocol offers an improvement
in the correlation of technical replicates and allows a higher pro-
portion of 5hmC sites to be called with statistical signiﬁcance,
the amount of input DNA required may prove limiting for many
users. However, validation using oxBS-pyroseq suggests that accu-
rate 5hmC levels, albeit at fewer sites, can nevertheless be called
using a lower input of 1 lg DNA for oxBS-450K analysis.Acknowledgements
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